This summer, the world situation is still evolving in the context of the still tense COVID-19 pandemic. However, oral Covid-19 treatment drugs have opened up new hope for ending the pandemic. Furthermore, the Olympic Tokyo 2020 is taking place with much effort after a year delay due to the epidemic.
Let’s take a look at some outstanding news in recent times with EZ! 😉
2020 TOKYO OLYMPICS OPENING CEREMONY
After a year being postponed by the Covid-19 pandemic, the 2020 Summer Olympic Games officially took place with the impressive Opening Ceremony in Japan – host country on July 23.
The Games opened while still in the shadow of Covid-19, with the Japanese capital under a state of emergency and many of the country’s residents adamantly opposed to holding the world sporting event at all.
As their ceremony played out, devoid of the usual crowd energy, spectators were prohibited from entering the ceremony grounds to prevent the pandemic spread. As a result, only about 1,000 people inside the Olympic stadium attended the opening ceremony, most of them are delegates and dignitaries, including the presence of Japan’s Emperor Naruhito, French President Emmanuel Macron, and US first lady Jill Biden on the VIP stand.
The opening ceremony of the Tokyo Olympic Games began with a colorful and light artistic program with the theme of “United by Emotion”. More than 1,800 drones were flown above the stadium during the ceremony, flying in patterns to form a globe and the Olympic emblem in the sky. Other performances are imbued with traditional Japanese beauty and synchronized with the emotions of the whole world at present.
The Japanese tennis world number two — Naomi Osaka, was the honor final Olympic flame torchbearer and lit the Olympic cauldron signifying the official start of the Games.
The Olympic motto is “Faster – Higher – Stronger”, but at the Tokyo Olympics 2020, this was added “Together”, becoming: “Faster – Higher – Stronger – Together”. Besides encouraging athletes to do their best and set new records, the slogan also wants to emphasize the spirit of solidarity in the context of the whole world having to deal with the Covid-19 pandemic.
The 2020 Summer Olympic Games are taking place between 23 July and 8 August with more than 11,300 athletes from 206 nations, competing for 339 medal sets in 33 sports, including 4 debut sports in Tokyo: karate, skateboarding, surfing, and sport climbing.
MOLNUPIRAVIR ORAL DRUG: EXPECTATION IN TREATING COVID-19 PATIENTS
The trial of the oral drug Molnupiravir brought promising results in the treatment of COVID-19 patients. According to US media, Merck Pharmaceutical Company (USA) and Ridgeback Biotherapeutics Company (Rigibel, Germany) have just announced that the oral drug Molnupiravirtreats COVID-19 for mild to moderate patients has shown promising results even though it is still in the phase 3 trial.
Molnupiravir, led by Germany Merck and Rigibel research and development experts, has completed 2 phases of clinical trials, achieving 100% effectiveness for all COVID-19 patients. After five days, the viral load of these patients dropped to the point of non-contagious. The Phase 3 clinical trial of 1,850 patients globally using Molnupiravir is nearing completion, and the results are expected to be published next fall. If successful, Merck will apply for an emergency use authorization and bring the drug to market in the next four to five months.
Molnupiravir is researched based on the original drug against influenza virus, which inhibits the replication of RNA viruses including SARS-CoV-2, causing the virus not to multiply and be eliminated very quickly, helping patients recover from illness. In particular, the drug has very few side effects. In addition, Molnupiravir is a drug that is easily taken orally, used to treat the early stages of the disease. The current trial regimen is two doses per day for 5 days.
If the phase 3 clinical trial is successful, future treatment for the SARS-CoV-2 virus will be similar to the treatment for other types of influenza.
Currently, the US has spent about $ 1.2 billion to buy 1.7 million courses of Molnupiravir to treat COVID-19 patients. Meanwhile, India’s Hetero laboratory is also seeking approval from the regulator for the drug Molnupiravir for use in an emergency program after initial trial studies showed the drug to reduce the proportion of patients requiring treatment effectively. Hospitalization and speeding up the recovery of mild COVID-19 patients.
Source: Vietnam News Agency
—–
#côngviêntiếnganhUEH #UEHEnglishZone#Cógìmớitrênthếgiới #What’snewaroundyou?